Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085742 | 0.86 | CRHR1 (0.56) | CRHR1CASRSMN1; SMN2 | |
| SCHEMBL3209738 | 0.84 | CRHR1 (0.43) | CRHR1CASRSMN1; SMN2 | |
| SCHEMBL2085396 | 0.81 | CRHR1 (0.41) | CRHR1CASR | |
| SCHEMBL3210010 | 0.81 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL2085909 | 0.81 | CRHR1 (0.50) | CRHR1CASR | |
| SCHEMBL2084151 | 0.80 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL2086149 | 0.79 | CRHR1 (0.42) | CRHR1SMN1; SMN2 | |
| SCHEMBL2084814 | 0.75 | CRHR1 (0.38) | CRHR1SMN1; SMN2 | |
| SCHEMBL3216688 | 0.74 | SMN1; SMN2 (0.46) | CRHR1SMN1; SMN2 | |
| SCHEMBL13459570 | 0.73 | CRHR1 (0.54) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | CRHR1 2/4885CASR 444/4885SMN1; SMN2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.